ClinicalTrials.gg
RecruitingNCT07325513SVM - GWIUpdated Apr 13, 2026

Machine Learning in Guiding rTMS Treatment for GWI-Related Headaches and Body Pain

An interventional study of Active Repetitive Transcranial Magnetic Stimulation and Active Repetitive Transcranial Magnetic Stimulation in Gulf War Illness, Headache and Muscle and Joint Pain, sponsored by Veterans Medical Research Foundation. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Veterans Medical Research Foundation · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 326 studies in Headache with a site in United States — 52 open to participants now, 65 under way, 5 of them phase 3. Headache · United States.

Planned enrollment
77th of 278
140 · median 64
Started
2026
with 17 others
No phase
128 of 326
25 open now
Primary completion
2029-10
later than 59 of 63 live
Registered
310th of 326
by date

Among the 326 studies in Headache with a site in United States, this one is the 77th largest by planned enrollment of the 278 interventional ones that give a count, is one of 18 that started in 2026, is one of 128 with no phase, reaches primary completion later than 59 of the 63 other live ones, and was the 310th registered.

Headache

764 studies on the registry are indexed under Headache; 134 are open to participants now.

Browse Headache studies →

Open to participants now

52 of the 326 studies in Headache with a site in United States are open now. Recruiting first, the newest first:

46 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 83 Headache studies recruiting now, 30 (36%) set no upper age limit and 44 (53%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 326 studies in Headache with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to create a machine learning algorithm to improve active repetitive transcranial magnetic stimulation (rTMS) treatments for veterans and/or active military personnel by alleviating Gulf War Illness related headaches and body pain (GWI-HAP). This study aims to develop and validate a Support Vector Machine (SVM) model that could replace the trial-and-error process by assessing functional connectivity provided by resting state functional magnetic resonance imaging (rs-fMRI) data to predict the most effective rTMS protocol for each person. All participants will be receiving active rTMS treatment.

The main questions it intends to answer are:

  1. Does the SVM model predict a more effective treatment response rate for predicted respondents undergoing active rTMS at the left dorsolateral prefrontal cortex (DLPFC) compared to predicted non-respondents?
  2. Does the SVM model predict a more effective treatment response rate while undergoing active rTMS at the left dorsolateral prefrontal cortex (DLPFC) and left motor cortex (LMC) in predicted respondents compared to predicted non-respondents?

Participants will undergo the following:

  1. Receive a total of 13 active rTMS treatment sessions over 3-4 months.
  2. Visit the clinic for a total of 15 visits for assessments, check ups, and treatments.
  3. Keep a daily log of their headaches, muscle and joint pain throughout the study.
Read the detailed description

This study aims to enroll a total of 140 veterans and/or active military personnel over the 4-year study period at the VA San Diego Healthcare System (VASDHS). Participants will be randomized into receiving treatments at the left DLPFC or left DLPFC and LMC, then placed into predicted respondent or non-respondent groups. They will be assigned to 1 of 4 groups:

Group A: Predicted Respondent at Left DLPFC Group B: Predicted Non-respondent at Left DLPFC Group C: Predicted Respondent at Left DLPFC and LMC Group D: Predicted Non-respondent at Left DLPFC and LMC

Participation in this study will require 15 total visits to the VASDHS over the course of 3-4 months. The visits will be separated in the following phases:

  1. Pre-Treatment Assessments Phase (Weeks 1-2): Visit 1 (Screening) and Visit 2 (Baseline Assessments)
  2. Induction Treatment Phase (Weeks 2-4): Visits 3-12 (Weekday active rTMS sessions at >24 hours and \<72 hours apart)
  3. Follow-Up and Maintenance Phase (Weeks 5-10): Visit 13 (1 week follow-up); Visit 14 (1 month follow-up); Visit 15 (2 months follow-up); All maintenance visits follow the final treatment of the induction phase.
03

Conditions studied

  • Gulf War Illness
  • Headache
  • Muscle and Joint Pain

Keywords

  • Repetitive Transcranial Magnetic Stimulation (rTMS)
  • Support Vector Machine (SVM)
  • Headache
  • Machine Learning
  • Muscle and Joint Pain
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female
  • Veteran or active military personnel
  • Between the ages of 18 and 65 years old
  • Served in the Persian Gulf region for at least 30 consecutive days between August 1, 1990, and July 31, 1991
  • Meets the CDC Criteria for GWVI (GWI), with symptoms starting during or after the 1990-1991 Persian Gulf deployment. Symptoms must be present for at least 6 months prior to enrollment in the study. Symptoms must be present in at least 2 of the 3 categories of fatigue, musculoskeletal, and mood cognitive.
  • Meets the Kansas Criteria for GWVI (GWI), with symptoms starting during or after the 1990-1991 Persian Gulf deployment. Symptoms must be present for at least 6 months prior to enrollment in the study. Qualifying symptoms must be at least moderate in severity and/or multiple symptoms must be present within at least 3 of 6 categories consisting of fatigue/sleep, neurological/cognitive/mood, pain, respiratory, gastroenterological, and dermatological symptomology.
  • Average Overall Daily Muscle Pain Intensity ≥3 on a 0-10 NPRS, present for at least 6 months
  • Average Overall Daily Extremities Joint Pain Intensity ≥3 on a 0-10 NPRS, present for at least 6 months
  • Average Headache Exacerbation Intensity ≥3 on a 0-10 NPRS, with headaches occurring for at least 6 months
  • Headache Exacerbation/attack ≥ 1 time per week with the average intensity ≥3 on a 0-10 NPS, lasting > 1 hour in the past three months
  • International Headache Society Criteria for Migraine Headache without aura

Exclusion criteria

Exclusion Criteria:

  • Children under the age of 18
  • Pregnant women
  • Individuals with cognitive/decisional impairment
  • Non-English speaking individuals
  • Prisoners of War
  • Incarcerated individuals
  • VA employees - including VA paid, IPA, or WOC
  • Students of the institution or of the investigator
  • Patients with cancer
  • History of pacemaker implant
  • Presence of ferromagnetic material (e.g., bullet fragment, shrapnel, device implant) in the brain or body that will prohibit the patients from having a brain MRI
  • History of dementia, major psychiatric diseases, or life-threatening diseases
  • Presence of any other chronic neuropathic pain states such as Complex Regional Pain Syndrome or Painful Peripheral Neuropathy
  • Known diagnosis of moderate to severe osteoarthritis and/or rheumatologic joint pain prior to the GWI deployment
  • Low back pain with mechanical origins such as lumbar radiculopathy or radiculitis or lumbar facet arthropathy
  • Concurrent conditions, like lupus, that can produce symptoms compatible with GWVI
  • History of seizure
  • Pending litigation
  • History of Traumatic Brain Injury-related headaches
  • Chronic Tension or Cluster Headache. However, subjects with occasional tension headaches (less than once every three months and lasting no more than 24 hours) will not be excluded from the study.
  • Ongoing Cognitive Rehabilitation or Treatment of PTSD
  • Recent exacerbation of anxiety disorder symptoms, active substance dependence, and/or current psychotic symptoms
  • Ongoing suicidal/homicidal ideation or recent (in the past 6 months) suicidal attempts
  • Patients who receive any narcotic-based analgesic, topical analgesics over the affected site, and local anesthetic injection, anticonvulsants, and antipsychotic medications less than 7 days prior to the pretreatment assessment
  • Patients who do not agree to avoid use of non-pharmacologic treatments, including but not limited to, transcutaneous electrical nerve stimulation unit (TENS), acupuncture, acupressure, and therapeutic massage during the entire study.
  • Patients who do not agree to use additional acetaminophen (up to a maximum total of 3g per day) as the only rescue medication
  • Patients who have received rTMS within the past 6 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Active comparator
    Group A: Predicted Respondent at LDLPFC

    Device: Active Repetitive Transcranial Magnetic Stimulation

  • Active comparator
    Group B: Predicted Non-respondent at LDLPFC

    Device: Active Repetitive Transcranial Magnetic Stimulation

  • Active comparator
    Group C: Predicted Respondent at LDLPFC and LMC

    Device: Active Repetitive Transcranial Magnetic Stimulation

  • Active comparator
    Group D: Predicted Non-respondent at LDLPFC and LMC

    Device: Active Repetitive Transcranial Magnetic Stimulation

Interventions

  • DeviceActive Repetitive Transcranial Magnetic Stimulation

    rTMS will be administered to the LDLPFC with an active coil.

  • DeviceActive Repetitive Transcranial Magnetic Stimulation

    rTMS will be administered to the LDLPFC with an active coil.

  • DeviceActive Repetitive Transcranial Magnetic Stimulation

    rTMS will be administered to the LDLPFC and LMC with an active coil.

  • DeviceActive Repetitive Transcranial Magnetic Stimulation

    rTMS will be administered to the LDLPFC and LMC with an active coil.

06

What researchers measure

Primary outcomes

  1. Pain Intensity - Mechanical Visual Analogue Scale (M-VAS)

    A scale that ranges from 0 to 10 ("No pain" to "Worst possible pain").

    Time frame: From baseline to the end of treatment at 16 weeks

  2. Headache and Pain Log

    A personal daily log is used to track the subject's headaches, muscle and joint pain throughout the course of the study based on a range of 0 to 10, with higher scores indicating more severe pain.

    Time frame: From enrollment to the end of treatment at 16 weeks

  3. Mood - Hamilton Rating Scale for Depression (HRSD)

    This scale is a well-established questionnaire which consists of twenty-one questions and rates the severity of symptoms observed in depression such as low mood, insomnia, agitation, anxiety and weight loss. Only the first 17 items are used for the overall scoring. A score between 14 and 18 represents a moderate form of depression and a score greater than 19 represents severe depression.

    Time frame: From baseline to end of treatment at 16 weeks

  4. Pain Severity - Brief Pain Inventory-Short Form (BPI-sf)

    This is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during the 24-hour period prior to evaluation. The BPI-sf consists of five questions. Four items measure pain on 11-point response scales from 0 to 10 ("No Pain" to "Pain as bad as you can imagine"). Another item, containing 7 sub-questions, evaluates the level of pain interference with daily functioning on 11-point response scales from 0 to 10 ("Does not interfere" to "Completely interferes"). Items 3-6 are summed together for a total average pain severity score.

    Time frame: Baseline, 1-week, 1-month, 2-months

  5. Pain Severity - Brief Pain Inventory-Short Form (BPI-sf)

    This is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during the 24-hour period prior to evaluation. The BPI-sf consists of five questions. Four items measure pain on 11-point response scales from 0 to 10 ("No Pain" to "Pain as bad as you can imagine"). Another item, containing 7 sub-questions, evaluates the level of pain interference with daily functioning on 11-point response scales from 0 to 10 ("Does not interfere" to "Completely interferes"). Items 9A-9G are summed together for a total pain interference score.

    Time frame: Baseline, 1-week, 1-month, 2-months

  6. Pain Quality and Intensity - Short Form McGill Pain Questionnaire (SF-MPQ)

    This is a self-report questionnaire that allows individuals to describe the quality and intensity of pain they are experiencing. This will be used to assess the sensory and affective aspects of muscle pain. The SF-MPQ consists of fifteen questions; items 1-11 are measured on a 4-point response scale ranging from 0 to 3 ("None" to "Severe"). Items 12-15 include a visual analogue scale (VAS) from "No pain" to "Worst possible pain" and Present Pain Intensity (PPI) ranging from 0 to 5 ("No pain" to "Excruciating") ranking overall pain intensity for a total average muscle pain score. This is calculated via the average VAS scores (0-100) with 0 indicating no pain and 100 equivalent to the worst pain possible.

    Time frame: Baseline, 1-week, 1-month, 2-months

  7. Pain Quality and Intensity - Short Form McGill Pain Questionnaire (SF-MPQ)

    This is a self-report questionnaire that allows individuals to describe the quality and intensity of pain they are experiencing. This will be used to assess the sensory and affective aspects of joint pain. The SF-MPQ consists of fifteen questions; items 1-11 are measured on a 4-point response scale ranging from 0 to 3 ("None" to "Severe"). Items 12-15 include a visual analogue scale (VAS) from "No pain" to "Worst possible pain" and Present Pain Intensity (PPI) ranging from 0 to 5 ("No pain" to "Excruciating") ranking overall pain intensity for a total average joint pain score. This is calculated via the average VAS scores (0-100) with 0 indicating no pain and 100 equivalent to the worst pain possible.

    Time frame: Baseline, 1-week, 1-month, 2-months

  8. Functionality - Revised Fibromyalgia Impact Questionnaire

    A questionnaire to evaluate the function, overall impact and symptoms of Fibromyalgia. The 3 categories are calculated by the sum of the scores to produce a total score. Each item ranges from 0-10 and the total score is 0-100 with high scores indicating more severe impact.

    Time frame: Baseline, 1-week, 1-month, 2-months

  9. Pain Intensity - New Clinical Fibromyalgia Diagnostic Criteria - Part 1

    Patients will be asked to rate the average (over the past week) intensity of muscle pain up to 12 locations of the body. This is calculated by the Widespread Pain Index (WPI) total score ranging from 0 to 19 and a marker visual analogue scale (MVAS) ranging from 0 to 100.

    Time frame: Baseline, 1-week, 1-month, 2-months

  10. Pain Severity - Headache Impact Test (HIT-6)

    This test measures how impact headaches affect the individual's ability to function in different domains. This six question test evaluates the severity of headache pain from "Never" to "Always" with a total range between 36-78, higher scores indicating greater impact on functionality.

    Time frame: Baseline, 1-week, 1-month, 2-months

  11. Pain Severity - Neurobehavioral Symptoms Inventory (NSI)

    This twenty-two self-report questionnaire on the severity of each symptom is measured using a 5-point response scale ranging from 0 to 4 ("None - Rarely if ever present; not a problem at all" to "Very Severe - Almost always present and I have been unable to perform at work, school or home due to this problem; I probably cannot function without help"). It asks the subjects to indicate the extent to which each symptom has disturbed them. The total score ranges from 0 to 88 with a higher score indicating very severe symptom disruption.

    Time frame: Baseline, 1-week, 1-month, 2-months

  12. Sleep Quality - Pittsburgh Sleep Quality Index (PSQI)

    This index has nineteen individual items which are used to generate 7 composite scores on: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The 7 components measure sleep habits and sum together to measure global sleep quality with a high score of 0-21 with a higher score indicating worse sleep quality.

    Time frame: Baseline, 1-week, 1-month, 2-months

  13. Sleep Severity - Insomnia Severity Index

    This index consists of seven questions that depict the severity of sleep difficulties within the past 2 weeks on a 5-point response scale that rates satisfaction, noticeability, distress, and interference with daily functioning. A score between 15 and 21 suggests moderately severe clinical insomnia. A score of 22 or greater represents severe clinical insomnia.

    Time frame: Baseline, 1-week, 1-month, 2-months

  14. Quality of Life - Veteran RAND 36-item Health Survey (VR-36+PCS and MCS)

    A patient-reported survey of patient health. It is a measure of health status and quality of life in regards to eight main areas: vitality, physical functioning, bodily pain, health perceptions, physical, emotional, and social role functioning and mental health.

    Time frame: Baseline, 1-week, 1-month, 2-months

  15. Multidimensional Fatigue Inventory

    A twenty item self-report instrument with 4 categories total designed to measure fatigue level (24-96) with a higher score indicating more severe fatigue.

    Time frame: Baseline, 1-week, 1-month, 2-months

  16. Chronic Fatigue Severity Scale

    A Likert scale consisting of nine items that assess fatigue severity and functionality. The sum of all questions provides total fatigue level 8-63 with a higher score being more severe. A score over 36 indicates patient may be suffering from fatigue.

    Time frame: Baseline, 1-week, 1-month, 2-months

Secondary outcomes

  1. Opiate/Medication Assessment

    This assessment evaluates opiate consumption over the duration of the study. Opioids and narcotics are converted to their morphine equivalent value on a daily basis. Values during each measurement period are added up and divided by the number of weeks to determine weekly usage.

    Time frame: From the baseline to the end of treatment at 16 weeks

07

Study locations

1 of 1 sites recruiting
  • Jennifer Moreno Department of Veterans Affairs Medical Center
    San Diego, California 92161, United States
    Recruiting
    • Caleb Lopez, B.S. · Contactcaleb.lopez@va.gov · 8585528585
    • Albert Leung, M.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Oct 2029, 43 months after the start.

Of 177 non-industry interventional studies with no phase under Headache, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 39. This study's planned 43 months is above that.

Counting every sponsor, half of 196 studies reached it within 14 months; a quarter within 6 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Jan 8, 2026
StartActual
Mar 25, 2026
Primary completionEst.
Oct 2029
CompletionEst.
Oct 2029
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07325513
Lead sponsor
Veterans Medical Research Foundation
Collaborators
San Diego Veterans Healthcare System, Congressionally Directed Medical Research Programs
Responsible party
Sponsor
First posted
Jan 8, 2026
Start date
Mar 25, 2026
Primary completion
Oct 2029 (estimated)
Completion
Oct 2029 (estimated)
Last update
Apr 13, 2026

Study contacts

Albert Y Leung, MD
Contact
ayleung@health.ucsd.edu
8585528585 ext. 3866
Caleb Lopez, BS
Contact
caleb.lopez@va.gov
8585528585 ext. 2638

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion